These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19802976)

  • 1. Growth curves of Escherichia coli and Pseudomonas aeruginosa submitted to different ceftazidime concentrations.
    Yourassowsky E; Van der Linden MP; Lismont ML; Crokaert F
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():127-30. PubMed ID: 19802976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis.
    Buijs J; Dofferhoff AS; Mouton JW; van der Meer JW
    J Antimicrob Chemother; 2007 May; 59(5):926-33. PubMed ID: 17395686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sub-inhibitory concentrations of ceftazidime and tobramycin reduce the quorum sensing signals of Pseudomonas aeruginosa.
    Garske LA; Beatson SA; Leech AJ; Walsh SL; Bell SC
    Pathology; 2004 Dec; 36(6):571-5. PubMed ID: 15841693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibacterial activity of 13 honeys against Escherichia coli and Pseudomonas aeruginosa.
    Wilkinson JM; Cavanagh HM
    J Med Food; 2005; 8(1):100-3. PubMed ID: 15857217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sub-minimum inhibitory concentrations of ceftazidime inhibit Pseudomonas aeruginosa biofilm formation.
    Otani S; Hiramatsu K; Hashinaga K; Komiya K; Umeki K; Kishi K; Kadota JI
    J Infect Chemother; 2018 Jun; 24(6):428-433. PubMed ID: 29449129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Regrowth in post-antibiotic period. A new approach based on the early response of the growth curve (author's transl)].
    Yourassowsky E; Van der Linden MP; Lismont MJ; Crokaert F
    Pathol Biol (Paris); 1982 Jun; 30(6):398-404. PubMed ID: 6810284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
    Mouton JW; Punt N; Vinks AA
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3449-51. PubMed ID: 17576831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Pluronic® F68 on ceftazidime biological activity in parenteral solutions.
    Dos Santos CA; Ribeiro GB; Knirsch MC; Pessoa Junior A; Penna TC
    J Pharm Sci; 2011 Feb; 100(2):715-20. PubMed ID: 20799363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa.
    Buyck JM; Luyckx C; Muccioli GG; Krause KM; Nichols WW; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2017 May; 72(5):1400-1409. PubMed ID: 28137941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of ceftazidime and other beta-lactam antibiotics against nosocomial strains of Pseudomonas aeruginosa.
    Santos Ferreira MO; Bacelar MJ; Canica MM
    J Int Med Res; 1984; 12(6):356-60. PubMed ID: 6440822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of synergy between ofloxacin, ceftazidime, and tobramycin against Pseudomonas aeruginosa.
    Madaras-Kelly KJ; Moody J; Larsson A; Baeker Hovde L; Rotschafer JC
    Chemotherapy; 1997; 43(2):108-17. PubMed ID: 9084919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bactericidal activity of ceftazidime against Pseudomonas aeruginosa under conditions simulating serum pharmacokinetic.
    Shah PM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():135-40. PubMed ID: 19802977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of ceftazidime against Pseudomonas aeruginosa from bacteraemic and fibrocystic patients.
    Fleming PC; Knie B
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():169-73. PubMed ID: 19802981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
    Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014).
    Sader HS; Castanheira M; Jones RN; Flamm RK
    Diagn Microbiol Infect Dis; 2017 Mar; 87(3):261-265. PubMed ID: 28069328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.
    Sy SK; Zhuang L; Beaudoin ME; Kircher P; Tabosa MA; Cavalcanti NC; Grunwitz C; Pieper S; Schuck VJ; Nichols WW; Derendorf H
    J Antimicrob Chemother; 2017 Apr; 72(4):1109-1117. PubMed ID: 28077672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.